Description
Repaglinide is a medication currently being studied in a clinical trial (NCT07372625) for patients with advanced solid tumors that have a specific mutation in the TP53 gene (Y220C). This trial is investigating how repaglinide affects the levels of other drugs (metformin, rosuvastatin, midazolam) in the body when taken alongside them. Repaglinide is typically used to treat type 2 diabetes by helping the pancreas release insulin. In this trial, it is being used in combination with other drugs and is not being studied as a direct treatment for colorectal cancer itself, but rather as part of a study looking at drug interactions in a specific patient population (those with the TP53 Y220C mutation). The trial is designed to see if the presence of the TP53 mutation affects how repaglinide is processed by the body and how it interacts with other common medications.
Mechanism of Action
Repaglinide is typically used to treat type 2 diabetes. It works by stimulating the pancreas to release insulin after meals. In the context of the clinical trial NCT07372625, repaglinide is being used to study drug interactions in patients with a specific TP53 mutation. The trial is investigating its effect on the pharmacokinetics (how the body processes) of other drugs, not its direct effect on cancer cells or the TP53 mutation itself.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.